Maalox plus Benadryl
Phase 3Small molecule
Maalox plus Benadryl is one of 9 small molecule programs targeting Aphthous Ulcer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Aphthous Ulcer
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Advil
KKenvue Brands
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Benadryl
PParkedale
Approved
Maalox plus Benadryl
TThe University of Texas Health Science Center, Houston
Phase 3
Peridex
DDexcel Pharma Technologies Ltd.
Preclinical
Coenzyme Q10
MMclean Hospital
Preclinical
Kenalog
MMichael Khazzam
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Maalox plus Benadryl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details